echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The road to the rise of China's innovative drugs: too much Lilly, too few Novo Nordisks

    The road to the rise of China's innovative drugs: too much Lilly, too few Novo Nordisks

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    How to become a cosmic pharmaceutical company? There is no standard answer to

    Looking back at the rise of overseas big pharmaceutical companies, there are two choices in front of domestic innovative pharmaceutical companies:

    The first is the "big and complete" model represented by Lilly: from diabetes to tumors to autoimmunity, Lilly has blossomed everywhere;

    The other is the "specialized and refined" model led by Novo Nordisk: in the 100-year history of Novo Nordisk, it has always been deeply engaged in the field of

    Although the two companies took two diametrically opposed routes, the results were very consistent, and both became leaders in the pharmaceutical industry:

    At present, Lilly has the second largest market capitalization in the world and Novo Nordisk has the sixth market capitalization in the

    As long as you care about research and development, no matter what model can be successful

    But which path is right for them, for Chinese biotechs who are in confusion, may need to ponder.

           / 01 /

    Lilly, a great and complete victory

    Who is the number one pharmaceutical company in the universe? Lilly laughed and said nothing

    Since 2019, in less than four years, Lilly's share price has risen by 184.
    56%, and its market value has increased by more than 200 billion US dollars, becoming the second largest pharmaceutical company
    after "drug and device complex" Johnson & Johnson.

    What is Eli Lilly? There is more than one answer, but reviewing its development path, one conclusion that can be drawn is the victory
    of the "big and complete" strategy.

    Lilly is extremely strong in diabetes, but its sphere of influence is not limited to this market
    As shown in the figure below, in addition to diabetes, Lilly is involved
    in the field of tumors, self-immunity, and neurological diseases.


    In terms of performance alone, diabetes is Lilly's trump card, contributing US$6.
    826 billion in revenue in the first half of 2022, accounting for half of the total

    In the long run, the growth of the company's diabetes business is far from over, dulaglutide and empagliflozin two blockbuster hypoglycemic drugs are still strong, and the GIP/GLP-1 dual receptor agonist tirzepatide is poised to go, which is regarded by many as a strong contender for the next drug king

    But Lilly's potential sector doesn't stop there, and the oncology business has a tendency
    to catch up.

    With the approval of adjuvant therapy indications for breast cancer last year, the revenue scale of the company's blockbuster product CDK4/6 inhibitor increased to US$1.
    058 billion in the first half of the year, an increase of 73%, which is one of
    the best performing drugs this year.

    In addition to CDK4/6 inhibitors, Lilly has also bet on RET, KRAS G12C, BTK, PI3Ka, which are popular tumor targets, and with the potential of the king of "me better", the future is destined to be full of interest

    Lilly's autoimmune disease field is late, but it is also rising rapidly, with revenue of $1.
    545 billion
    in the first half of the year.

    At present, in addition to expanding the indications of IL-17A inhibitors, Lilly is also developing self-exempt star targets such as IL-2, IL-23, and IL-13
    It can be seen that Lilly is also full of expectations
    in the field of autoimmune diseases.

    At the same time, Lilly is also incubating the neurological disease business
    In the first half of the year, although this segment contributed only 788 million US dollars in revenue, it contained potential future blockbuster bomb products - Alzheimer's disease drugs

    Overall, Lilly's rise has opened and closed, based on the continuous extension of its own circle of competence, it has found many growth points outside the diabetes market, and jointly supported the company's bright future

           / 02 /

    Novo Nordisk, a triumph of fineness and specialization

    In the pharmaceutical rivers and lakes, "big and complete" can succeed, and "small and beautiful" can not stand out

    "Small" means focusing, looking at an area and doing it best
    At this point, Novo Nordisk has the most right to

    In the past nearly 100 years, Novo Nordisk has been continuously engaged
    in the field of diabetes.
    According to the company's 2021 financial report, its diabetes business revenue reached 17.
    996 billion US dollars, accounting for 80% of
    the total revenue.


    In addition to diabetes, the Novo Nordisk pipeline focuses on obesity and rare diseases
    Among them, obesity is also an extension of diabetes products


    But focusing does not mean that it is difficult to become a cosmic big pharmaceutical company
    Over the past decade, Novo Nordisk's share price has risen nearly 5 times, making it one of the pharmaceutical companies with the highest rate of return; Up to now, Novo Nordisk has a market value of 240.
    4 billion US dollars, ranking 6th in the world.

    As mentioned above, Novo Nordisk's success comes from "precision and expertise"

    Since the invention of the first generation of animal insulin in 1925, Novo Nordisk's R&D iteration has not stopped
    From improving safety, improving efficacy, to extending safety time, insulin from second generation to fourth generation, Novo Nordisk has been a

    The ultimate pursuit of technology has created the hegemonic position
    of Novo Nordisk.
    In the first half of 2022, Novo Nordisk's insulin accounted for 47.
    1% of the global market share

    Novo Nordisk's ultimate pursuit is not limited to insulin, but also includes another hypoglycemic drug, the GLP-1 analogue.

    In 2009, Novo Nordisk launched the world's first GLP-1 analogue liraglutide, ushering in a new era of hypoglycemia; In 2017, Novo Nordisk launched the long-acting hypoglycemic drug semeglutide

    Around semeglutide, Novo Nordisk once again exerted its own "refined and specialized" research, by expanding indications, increasing doses, and combining with other drugs, trying to tap all the potential
    of semeglutide.

    At present, semeglutide has become the ruler of
    the GLP-1 field.
    Driven by it, Novo Nordisk occupied 31% of the global hypoglycemic drug market share
    at the end of 2021.

    Hypoglycemic drugs have also brought Novo Nordisk an unexpected "side hustle" - the weight loss market
    In June 2021, the FDA approved semeglutide for weight
    Morgan Stanley expects Novo Nordisk obesity revenue to reach $11.
    7 billion in 2030, opening a new growth engine

    100 years of expertise in the field of diabetes is the source
    of Novo Nordisk's ingenuity.

           / 03 /

    China's innovative pharmaceutical companies also need more ingenuity

    Lilly's model is worth learning, and Novo Nordisk's model can also be learned

    In the future, we will inevitably give birth to China's "Lilly"
    Nowadays, many innovative pharmaceutical companies are pursuing a "big and complete" development model

    Most of the "three tigers" of biopharma that were successfully transformed by biotech due to PD-1 are like this

    Innovent Biologics still focuses on oncology business, but is not limited by oncology business: self-immunity, ophthalmology, and metabolism have all been deployed

    Junshi's metamorphosis seems to be more thorough, and the key to supporting its imagination in the past two years is the new crown business: from neutralizing antibodies to new crown oral drugs

    It is also understandable that the domestic innovative drug industry is still a desert, and there are many areas that need to be overcome
    The transition from generic to innovative drugs is destined to be full of opportunities
    In the face of historical opportunities, naturally no one wants to miss them

    It is precisely for this reason that many domestic innovative pharmaceutical companies have opened up and closed at the beginning of their establishment and attacked
    in the direction of "big and complete".
    In the future, it is destined to give birth to a king and lead China's innovative drugs to the world

    But at the same time as the rise of "China Lilly", we also look forward to the birth of industry cultivators
    such as Novo Nordisk.

    Everyone in domestic innovative drug companies is "Lilly", and there is helplessness behind it
    From 2015 to now, the development of the domestic innovative drug industry has
    been completed in only 7 years.
    Most innovative pharmaceutical companies are still very young and in the stage
    of entrepreneurship and financing.

    Innovative pharmaceutical companies first need to ensure that they can continue to raise funds before they are qualified to talk about the future
    That's why everyone goes wherever
    it's hot.

    Typical such as Huadong Medicine, centralized procurement to compress the profit of generic drugs, the road of transformation is colorful, from medical cosmetology to ADC, and then to today's diet drugs, hot spots have never been absent

    In the field of new crown oral drugs, pharmaceutical companies are better at chasing hot spots
    Pharmaceutical companies that used to do AIDS drugs, hepatitis B drugs, and everything are all lined up to enter the list
    of new crown concept stocks.

    Returning to the level of development path, for the capital market, it must be that the "large and complete" model is more attractive

    Under the constraint of capital, there are only a few
    pharmaceutical companies that can stand alone and are willing to develop drugs with ingenuity.

    Nowadays, as the capital boom fades, the domestic innovative drug industry is about to enter a new development cycle
    Although Novo Nordisk's model may not be replicable, domestic pharmaceutical companies should also take this case to seriously consider:

    Which path is more suitable for you?

    If this article violates your rights, please contact us

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.